<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52042">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02019030</url>
  </required_header>
  <id_info>
    <org_study_id>5130322</org_study_id>
    <nct_id>NCT02019030</nct_id>
  </id_info>
  <brief_title>Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode</brief_title>
  <official_title>Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode - An Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Olympus Corporation of the Americas</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Olympus Corporation of the Americas</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to evaluate the outcomes of using the
      PlasmaButton electrode in the treatment on Benign Prostatic Hyperplasia while on
      anticoagulation medication.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Complication rates when the PlasmaButton Electrode is used to perform TUVP ransurethral Vaporization of the Prostate) on patients on anticoagulants</measure>
    <time_frame>Introperative</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of subjective patient improvement on the International Prostate Symptom Score questionnaire</measure>
    <time_frame>Before surgery and 1, 3, 6 month follow up visits</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of subjective patient improvement on the Sexual Health for Men (SHIM) score</measure>
    <time_frame>Before surgery and 1, 3, 6 month follow-up</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of maximum urine flow rate as measured by urine flowmetry</measure>
    <time_frame>Before surgery and 1, 3, 6 month follow-up</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Benign prostatic hyperplasia, anticoagulation</arm_group_label>
    <description>Patients who have Benign Prostatic Hyperplasia undergoing Transurethral Vaporization of Prostate and are on anticoagulant medication</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Symptomatic BPH patients seen at Urology clinic at Loma Linda University Medical Center
        and VA Greater Los Angeles Healthcare System
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men with obstructive symptoms due to benign prostatic hyperplasia who are also on
             anticoagulant regiment.

          -  Anticoagulant regiments include: Aspirin 81mg, Aspirin 325mg, Adenosine diphosphate
             (ADP) receptor inhibitors, Cilostazol, Dabigatran, Dipyridamole, or Warfarin. The
             patient will be stable on their dosage regimen for at least 3 months.

          -  Maximum flow rate &lt;15ml/s by uroflowmetry.

          -  International Prostate Symptom Score (IPSS)â‰¥10.

        Exclusion Criteria:

          -  Patients with coagulopathy, INR exceeding 3.

          -  Anti-coagulation dose changes within 3 months of surgery.

          -  Patients not medically cleared to undergo surgery for medical reasons.

          -  Patients with neurogenic bladder (bladder affected due to a neurologic cause).

          -  Urethral stricture, obstruction due to stricture.

          -  Suspected bladder or prostate cancer.

          -  Prostate size greater than 80 cc.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hadley, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carol J Bennett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Greater Los Angeles Healthcare System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Hadley, MD.</last_name>
    <phone>909-558-4000</phone>
    <phone_ext>44196</phone_ext>
    <email>davidhadley@llu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Loma Linda University Medical Center Urology Department</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Hadley, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Herbert C. Ruckle, MD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edmund Ko, MD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Greater Los Angeles Healthcare System</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Carol J Bennett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 17, 2013</lastchanged_date>
  <firstreceived_date>December 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>benign prostatic hyperplasia</keyword>
  <keyword>Transurethral vaporization of prostate</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
